Amsterdam UMC spin-off TrianecT secures investment of €1.35 million for superfast stroke diagnostics
XO Ventures and CbusineZ are jointly investing €1.35 million in Amsterdam UMC spin-off TrianecT BV, an innovative MedTech company specializing in acute stroke diagnostics. The investment will support the commercial development and market launch of StrokePointer™, a portable device that can diagnose a stroke while the patient is still in the ambulance.
Thanks to this investment—and the strategic involvement of our new partners—we can accelerate the translation of our technology from scientific breakthrough to real-world application.
About the innovation
One-third of global healthcare costs are spent on strokes. Rapid and accurate treatment is crucial—every minute counts. StrokePointer™ enables ambulance professionals to immediately recognize a severe stroke, such as an LVO (large vessel occlusion), and transport patients directly to a specialized treatment center. This improves patient outcomes and contributes to more eSicient care
History of TrianecT
TrianecT was founded in 2022 as a spin-off from Amsterdam UMC and Neuromotion Ventures. Before, in 2018 Wouter Potters and Jonathan Coutinho won the Amsterdam Science & Innovation Awards when the innovation was still in an early stage. The latest investment round was led by XO Ventures, an early-stage, hands-on health/tech investor and part of XO Capital, a single-family office.
I've been proud to support TrianceT every step of the way, from shaping the business plan and joining the Venture Challenge, to advising on funding, legal, IP and contractual matters. It’s been rewarding to help setting up this company around data and AI.
